Skip to main content
main-content
Top

RESILIENT trial

This is a phase II/III trial of an injectable liposomal formulation of irinotecan in individuals who have progressed during or after initial treatment with platinum-based chemotherapy.

Results from the dose-finding part of the trial will be reported at WCLC 2019:

Title: Initial efficacy and safety results of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer
Presenter: Luis Paz-Ares Rodríguez, Hospital 12 de Octubre, Madrid, Spain
Sunday, 8 September: 13:50–14:00 (Abstract OA03.03)

Back to the WCLC 2019 conference hub